IP Library Granted Patent US 11,707,454
Granted Patent B2
US 11,707,454 · App. 17/542,072 · Granted Jul 25, 2023

Topical roflumilast formulation having antifungal properties

Inventors: David Reuben Berk (Westlake Village, CA); Patrick Eugene Burnett (Westlake Village, CA); Saori Kato (Westlage Village, CA); David W. Osborne (Fort Collins, CO)
Assignee: Arcutis Biotherapeutics, Inc.
A61K31/44A61K9/0014A61K31/137A61K31/27A61K31/343A61K31/4174A61K31/4418A61K31/496A61K31/506A61K31/60A61K33/04A61K45/06A61K47/06A61K47/10A61K47/14A61K47/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,707,454
App. No.
17/542,072
Granted
Jul 25, 2023
Kind
B2
Abstract

The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis , and/or Tinea incognito . Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

Claims (48)

1. A method of treating a fungal infection in a subject in need thereof, comprising administering to the subject a composition comprising an antifungal effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the fungal infection is caused by Malassezia spp.

2. The method according to claim 1 , wherein said roflumilast is administered topically.

3. The method according to claim 1 , wherein said Malassezia spp. is selected from the group consisting of M. furfur, M. restricta , and M. globosa.

4. The method according to claim 3 , wherein said Malassezia spp. is M. furfur.

5. The method according to claim 1 , wherein the fungal infection comprises fungal overgrowth of hair, skin or nails.

6. The method according to claim 1 , wherein said subject is suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis , or Tinea incognito.

7. The method according to claim 6 , wherein said subject is suffering from seborrheic dermatitis.

8. The method according to claim 1 , wherein said composition comprises carriers suitable for topical administration.

9. The method according to claim 1 , wherein said composition is selected from the group consisting of an aerosol, a foam, a spray, an emulsion, a gel, a liquid, an ointment, a paste, a shampoo, a suspension, and a system.

10. The method according to claim 9 , wherein said composition is a foam.

11. The method according to claim 1 , wherein said composition comprises 0.3% w/w roflumilast.

12. The method according to claim 1 , wherein said composition comprises roflumilast, white petrolatum, isopropyl palmitate, cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate, hexylene glycol, diethylene glycol monoethyl ether, methylparaben, propylparaben and water.

13. The method according to claim 1 , wherein said composition consists of:

roflumilast

0.3%

w/w

white petrolatum

10.0%

w/w

isopropyl palmitate

5.0%

w/w

cetearyl alcohol,

10.0%

w/w

dicetyl phosphate

and ceteth-10

phosphate blend

hexylene glycol

2.0%

w/w

diethylene glycol

25.0%

w/w

monoethyl ether

methylparaben

0.2%

w/w

propylparaben

0.05%

w/w, and

purified water

q.s. ad 100

(47.45%).

14. The method according to claim 1 , further comprising administering an additional anti-fungal agent and/or an anti-inflammatory agent.

15. The method according to claim 14 wherein said additional anti-fungal agent is selected from the group consisting of: drugs containing miconazole, ciclopirox olamine, clotrimazole, butenafine, terbinafine, amorolfine, naftifine, tolnaftate, ketoconazole, efinaconazole, griseofulvin, imidazoles, triazole, voriconazole, benzimidazole, ethylparaben, flucytosine, salicylic acid, selenium sulfide, and undecylenic acid.

16. The method according to claim 14 wherein said additional anti-inflammatory agent is a corticosteroid or a calcineurin inhibitor.

17. A method of treating a fungal infection, fungal overgrowth and/or hypersensitivity to Malassezia spp in a subject in need thereof, comprising topically administering to the subject an antifungal effective amount of roflumilast or a pharmaceutically acceptable salt thereof, wherein the fungal infection or overgrowth is caused by Malassezia spp.

Assignments (2)
SECURITY INTEREST Recorded Aug 9, 2024
From: ARCUTIS BIOTHERAPEUTICS, INC.
To: SLR INVESTMENT CORP.
Reel/Frame 068236/0418 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2022
From: BERK, DAVID REUBEN; BURNETT, PATRICK EUGENE; KATO, SAORI; OSBORNE, DAVID W.
To: ARCUTIS BIOTHERAPEUTICS, INC.
Reel/Frame 058719/0232 →
Continuity (2)
Provisional Application 63121299 · Dec 4, 2020
Related Publication 20220175743A1 · Jun 9, 2022
Cited By (9)
US 12,220,409 US 12,257,242 US 12,310,956 US 12,329,751 US 12,336,983 US 12,390,453 US 12,453,721 US 12,685,727 US 12,697,329